Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism
versus subjects using a placebo, who lost an average of 1.25 lbs
Genetics can play a role, but lifestyle and environmental factors are often the primary drivers, along with a poor diet and lack of physical activity
Patients typically experience a 15 to 20 percent reduction in body weight
